VectivBio Holding AG (VECT)

CH1109007893 - Common Stock

16.85  0 (0%)

Fundamental Rating

2

Overall VECT gets a fundamental rating of 2 out of 10. We evaluated VECT against 588 industry peers in the Biotechnology industry. The financial health of VECT is average, but there are quite some concerns on its profitability. VECT is valued expensive and it does not seem to be growing.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year VECT has reported negative net income.
In the past year VECT has reported a negative cash flow from operations.

1.2 Ratios

The profitability ratios for VECT are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

VECT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for VECT has been increased compared to 1 year ago.
Compared to 1 year ago, VECT has a worse debt to assets ratio.

2.2 Solvency

VECT has an Altman-Z score of 17.24. This indicates that VECT is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 17.24, VECT belongs to the best of the industry, outperforming 93.55% of the companies in the same industry.
A Debt/Equity ratio of 0.05 indicates that VECT is not too dependend on debt financing.
VECT has a Debt to Equity ratio of 0.05. This is comparable to the rest of the industry: VECT outperforms 40.16% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z 17.24
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

VECT has a Current Ratio of 9.14. This indicates that VECT is financially healthy and has no problem in meeting its short term obligations.
VECT has a Current ratio of 9.14. This is in the better half of the industry: VECT outperforms 71.13% of its industry peers.
A Quick Ratio of 9.14 indicates that VECT has no problem at all paying its short term obligations.
VECT has a better Quick ratio (9.14) than 71.29% of its industry peers.
Industry RankSector Rank
Current Ratio 9.14
Quick Ratio 9.14

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 22.00% over the past year.
EPS 1Y (TTM)22%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-11.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

VECT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.85% yearly.
Based on estimates for the next years, VECT will show a very strong growth in Revenue. The Revenue will grow by 81.29% on average per year.
EPS Next Y8.67%
EPS Next 2Y1.86%
EPS Next 3Y1.79%
EPS Next 5Y19.85%
Revenue Next Year-96.99%
Revenue Next 2Y-36.77%
Revenue Next 3Y44.85%
Revenue Next 5Y81.29%

3.3 Evolution

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VECT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VECT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.86%
EPS Next 3Y1.79%

More info and screens

0

5. Dividend

5.1 Amount

VECT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VectivBio Holding AG

NASDAQ:VECT (7/7/2023, 7:07:59 PM)

16.85

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.06B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 9.14
Quick Ratio 9.14
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)22%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y8.67%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y